Cwm LLC Has $1.05 Million Holdings in Agilent Technologies, Inc. (NYSE:A)

Cwm LLC boosted its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 12.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,559 shares of the medical research company’s stock after purchasing an additional 836 shares during the period. Cwm LLC’s holdings in Agilent Technologies were worth $1,051,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of A. DAVENPORT & Co LLC acquired a new stake in Agilent Technologies during the 3rd quarter valued at $307,000. Oak Thistle LLC acquired a new stake in Agilent Technologies during the 3rd quarter valued at $426,000. Handelsbanken Fonder AB boosted its position in Agilent Technologies by 0.5% in the 3rd quarter. Handelsbanken Fonder AB now owns 141,790 shares of the medical research company’s stock valued at $15,855,000 after buying an additional 687 shares during the last quarter. Ballentine Partners LLC boosted its position in Agilent Technologies by 41.0% in the 3rd quarter. Ballentine Partners LLC now owns 3,826 shares of the medical research company’s stock valued at $428,000 after buying an additional 1,113 shares during the last quarter. Finally, Valeo Financial Advisors LLC bought a new position in Agilent Technologies in the 3rd quarter valued at $213,000.

Insider Activity at Agilent Technologies

In related news, SVP Philip Binns sold 2,827 shares of Agilent Technologies stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total transaction of $417,095.58. Following the completion of the transaction, the senior vice president now owns 9,997 shares in the company, valued at $1,474,957.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, SVP Philip Binns sold 2,827 shares of Agilent Technologies stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total transaction of $417,095.58. Following the completion of the transaction, the senior vice president now owns 9,997 shares in the company, valued at $1,474,957.38. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Rodney Gonsalves sold 4,828 shares of Agilent Technologies stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $149.00, for a total value of $719,372.00. Following the transaction, the vice president now owns 21,329 shares of the company’s stock, valued at approximately $3,178,021. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,610 shares of company stock valued at $9,220,333.

Wall Street Analyst Weigh In

A number of research analysts have commented on A shares. Evercore ISI increased their price objective on Agilent Technologies from $132.00 to $145.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. UBS Group increased their price objective on Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. Citigroup increased their price objective on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. Stifel Nicolaus upgraded Agilent Technologies from a “hold” rating to a “buy” rating and increased their price objective for the company from $145.00 to $163.00 in a research report on Friday, April 5th. Finally, Oppenheimer raised their price target on Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $141.29.

Agilent Technologies Stock Performance

A opened at $137.74 on Friday. The business’s 50-day moving average price is $141.59 and its two-hundred day moving average price is $130.68. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $151.58. The company has a market capitalization of $40.36 billion, a price-to-earnings ratio of 32.80, a P/E/G ratio of 4.13 and a beta of 1.11. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.68 and a quick ratio of 2.04.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.07. The firm had revenue of $1.66 billion for the quarter, compared to the consensus estimate of $1.59 billion. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company’s revenue for the quarter was down 5.5% on a year-over-year basis. During the same quarter last year, the business posted $1.37 EPS. Equities analysts expect that Agilent Technologies, Inc. will post 5.5 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd were given a $0.236 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date was Monday, April 1st. Agilent Technologies’s dividend payout ratio is currently 22.38%.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.